Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine group B - GSK

Next Previous
X
Search
Drug Profile

Meningococcal vaccine group B - GSK

Alternative Names: 4CMenB; Bexsero; Four component, meningococcal serogroup B vaccine (4CMenB) - GSK; GSK-3536829; GSK-3536829A; MenB; MenB+OMV NZ - GSK; Meningococcal B recombinant vaccine - GSK; Multi-component meningococcal B vaccine (Bexsero) - GSK; rMenB+OMV NZ

Latest Information Update: 01 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norwegian Institute of Public Health; Novartis
  • Developer GSK; Novartis
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group B infections

Most Recent Events

  • 22 Jul 2024 GSK completes the phase-III MENB REC 2ND GEN-045 (V72_79) trial in Meningococcal infections (In adolescents, Prevention) in USA and Italy (IM), (NCT04318548),
  • 24 May 2024 Phase-III clinical trials in Meningococcal group B infections (In infants, In children, In adolescents, In adults, In the elderly, Prevention) in USA (IM) (GSK Pipeline, May 2024)
  • 13 Sep 2022 GlaxoSmithKline completes its phase III trial for Meningococcal B infections (In adults, In adolescents, In volunteers) in USA, Australia, Finland, Turkey, Canada, Czech Republic and Estonia (NCT04502693)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top